Geron Co. (NASDAQ:GERN) has been assigned an average rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $3.75.
A number of equities analysts have recently commented on GERN shares. BidaskClub upgraded shares of Geron from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 11th. Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd.
Geron (NASDAQ GERN) traded up $0.13 during mid-day trading on Wednesday, hitting $2.93. 3,504,560 shares of the stock were exchanged, compared to its average volume of 2,970,000. Geron has a one year low of $1.74 and a one year high of $3.15. The company has a market capitalization of $466.55, a price-to-earnings ratio of -16.28 and a beta of 2.77.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3258171/geron-co-gern-receives-3-75-consensus-price-target-from-analysts.html.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.